Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Journal of the European Academy of Dermatology and Venereology : JEADV（2023）
摘要
Tildrakizumab was effective and safe in a large cohort of patients with moderate-to-severe plaque psoriasis treated in a routine clinical setting.
更多查看译文
关键词
Psoriasis,clinical practice,effectiveness,persistence,real-world evidence,safety,tildrakizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要